[1]任翔,孙嘉,王明.血管紧张素转换酶2与糖尿病肾病[J].国际内分泌代谢杂志,2014,(01):53-56.[doi:10.3760/cma.j.issn.1673-4157.2014.01.015]
　Ren Xiang*,Sun Jia,Wang Ming.Relationship between angiotensin-converting enzyme 2 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(01):53-56.[doi:10.3760/cma.j.issn.1673-4157.2014.01.015]
点击复制

血管紧张素转换酶2与糖尿病肾病()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年01期
页码:
53-56
栏目:
综述
出版日期:
2014-02-28

文章信息/Info

Title:
Relationship between angiotensin-converting enzyme 2 and diabetic nephropathy
作者:
任翔; 孙嘉; 王明
510282　广州,南方医科大学第二临床医学院（任翔）；510282　广州,南方医科大学珠江医院内分泌科（孙嘉）,中西医结合肾病中心（王明） 　　
Author(s):
Ren Xiang*; Sun Jia; Wang Ming．
*Second Medical School of Southern Medical University,Guangzhou 510282,China Corresponding author：Wang Ming,Email：wming1999@163.com
关键词:
血管紧张素转换酶2; 糖尿病肾病
Keywords:
Angiotensin-converting enzyme 2; Diabetic nephropathy
DOI:
10.3760/cma.j.issn.1673-4157.2014.01.015
摘要:
血管紧张素转换酶2（ACE2）通过将血管紧张素Ⅱ（AngⅡ）降解为Ang-（1-7）,具有舒张血管、抑制平滑肌细胞增生、抗纤维化等效应,与多种疾病密切相关。在糖尿病肾病（DN）中,ACE2可通过影响组织微循环进而对糖代谢以及肾组织病变产生作用,也可通过改变机体氧化应激水平、影响肾小管上皮-间充质转分化等参与DN的病变过程。近年来,ACE2已逐渐成为一个疾病的标志物和药物治疗的新靶点,ACE2不仅影响DN的发生、发展,也为其诊断和治疗提供了新的方法和策略。
Abstract:
Angiotensin-converting enzyme 2（ACE2） plays an important role in vasodilation,antiproliferation and anti-fibrosis through enhancing the degradation of Angiotensin Ⅱ to Ang-（1-7）,which is closely related with many diseases.In diabetic nephropathy,it is associated with glucose metabolism and renal lesions through regulating microcirculation.It can also change the level of oxidative stress and induce the epithelial-mesenchymal of kidney,thus participate in the development of diabetic nephropathy. And it gradually becomes a new biomarker of some diseases and a new target of medicine therapy.Recent studies indicate that ACE2 not only influences the development of diabetic nephropathy,also offers some new diagnostic and therapeutic strategies.

参考文献/References:

　[1]　Tikellis C,Thomas MC．Angiotensin-converting enzyme 2 （ACE2） is a key modulator of the renin angiotensin system in health and disease[J]．Int J Pept,2012,2012：256-294. 　
[2]　Iwai M,Horiuchi M．Devil and angel in the renin-angiotensin system：ACE-angiotensinⅡ-AT1 receptor axis vs．ACE2-an-giotensin-（1-7）-Mas receptor axis[J]．Hypertens Res,2009,32（7）：533-536. 　
[3]　Ferreira AJ,Shenoy V,Qi Y,et al．Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases[J]．Exp Physiol,2011,96（3）：287-294. 　
[4]　Fraga-Silva RA,Sorg BS,Wankhede M,et al．ACE2 activation promotes antithrombotic activity[J]．Mol Med,2010,16（5-6）：210-215. 　
[5]　Song B,Jin H,Yu X,et al．Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways[J]．Regul Pept,2013,185：44-51. 　
[6]　Fang HJ,Yang JK．Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas[J]．J Int Med Res,2010,38（2）：558-569. 　
[7]　Yuan L,Wang Y,Lu C,et al．Angiotensin-ｃonverting ｅnzyme 2 ｄeficiency ａggravates ｇlucose ｉntolerance via ｉmpairment of ｉslet ｍicrovascular ｄensity in ｍice with ｈigh-ｆat ｄiet[J]．J Diabetes Res,2013,2013：405284. 　
[8]　王珊珊,马畅,张伟,等．血管紧张素转化酶2（ACE2）在糖尿病大鼠肾损伤中的作用及机制分析[J]．食品科学,2013,34（9）：287-291. 　
[9]　Jarajapu YP,Bhatwadekar AD,Caballero S,et al．Activation of the ACE2/angiotensin-（1-7）/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progen-itors[J]．Diabetes,2013,62（4）：1258-1269.
[10]　Zhong J,Guo D,Chen CB,et al．Prevention of angiotensin Ⅱ-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2[J]．Hypertension,2011,57（2）：314-322.
[11]　Shiota A,Yamamoto K,Ohishi M,et al．Loss of ACE2 acceler-ates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice [J]．Hypertens Res,2010, 33（4）：298-307.
[12]　Harris RC．Podocyte ACE2 protects against diabetic nephropathy[J]．Kidney Int,2012,82（3）：255-256.
[13]　Nadarajah R,Milagres R,Dilauro M,et al．Podocyte-specific overexpression of human angiotensin-converting enzyme 2 at-tenuates diabetic nephropathy in mice[J]．Kidney Int,2012,82（3）：292-303.
[14]　陈欢,沈洁,李章芳,等．ACE2对糖尿病大鼠肾小球足细胞的影响及厄贝沙坦干预作用的研究[J].国际内分泌代谢杂志, 2013,33（2）：76-80.
[15]　Zhou L,Xue H,Wang Z,et al．Angiotensin-（1-7）attenuates high glucose-induced proximal tubular epithelial-to-mesenchymal transition via inhibiting ERK1/2 and p38 phosphorylation[J]． Life Sci,2012,90（11-12）：454-462.
[16]　Burns WC,Velkoska E,Dean R,et al．Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7/MAS-1-dependent pathways[J]．Am J Physiol Renal Physiol,2010,299（3）：F585-F593.
[17]　Wysocki J,Garcia-Halpin L,Ye M,et al．Regulation of urinary ACE2 in diabetic mice[J]．Am J Physiol Renal Physiol,2013,305（4）：F600-F611.
[18]　Mizuiri S,Aoki T,Hemmi H,et al．Urinary angiotensin-converting enzyme 2 in patients with CKD[J]．Nephrology（Carlton）,2011, 16（6）：567-572.
[19]　Xiao F,Hiremath S,Knoll G,et al．Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes[J]．PLoS One,2012,7（5）：e37649.
[20]　Oudit GY,Liu GC,Zhong J,et al．Human recombinant ACE2 reduces the progression of diabetic nephropathy[J]．Diabetes,2010,59（2）：529-538.
[21]　Liu CX,Hu Q,Wang Y,et al．Angiotensin-converting enzyme （ACE） 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy：a comparison with ACE inhibition[J]．Mol Med,2011,17（1-2）：59-69.
[22]　李永勤,吴娟娟,高登峰,等.替米沙坦对高血压并糖尿病患者血管紧张素转换酶2 mRNA表达的影响.中华内科杂志,2013,52（1）：26-29.
[23]　Giani JF,Burghi V,Veiras LC,et al．Angiotensin-（1-7） atten-uates diabetic nephropathy in Zucker diabetic fatty rats[J]． Am J Physiol Renal Physiol,2012,302（12）：F1606-F1615.
[24]　Fraga-Silva RA,Costa-Fraga FP,Murca TM,et al．Angiotensin-converting enzyme 2 activation improves endothelial function[J]． Hypertension,2013,61（6）：1233-1238.

相似文献/References:

[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
　Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[4]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
　Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
　Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
　Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[8]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
　Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
　Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
　An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]

备注/Memo

备注/Memo:
基金项目：广东省自然基金博士启动项目 （S2012040007106）；广东省医学科研基金（B2013252）; 广东省大学生创新实验项目(1212112014) 通信作者：王明,Email:wming1999@163.com
更新日期/Last Update: 2014-01-20